EarningsQ2 2026 Earnings Report
DE:2LB Q2 2026 EPS Results
Actual EPS-€0.10
Consensus EPS-€0.12
Beat/MissBeat by +€0.02
One Year Ago EPS-€0.29
DE:2LB Q2 2026 Revenue Results
Actual Revenue€88.64M
Expected Revenue€78.39M
Beat/MissBeat by +€10.25M
YoY Revenue Growth+65.65%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
DE:2LB Upcoming Earnings
Iovance Biotherapeutics's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2LB Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and meaningful operational progress: record revenue ($99.3M), a best-ever 56% gross margin, accelerating Amtagvi uptake (~$91M revenue, +51% sequential and +68% YoY), expanding ATC footprint (>95 ATCs), and important pipeline/regulatory milestones (LUN-202 near-complete enrollment, SARATOGA Fast Track). Key challenges include limited sample sizes in some early efficacy readouts, pending international reimbursement/approvals, near-term guidance review, and the need to sustain funding for continued scale and trials. On balance, the positive commercial momentum, margin expansion, pipeline advancement, and disciplined cost management significantly outweigh the near-term uncertainties.Company Guidance
Record Quarterly Revenue
Total revenue of $99.3M in Q2 2026, up 66% year-over-year and 39% sequentially; Amtagvi drove growth with approximately $91M in revenue, exceeding guidance of $79M–$81M.
All-Time High Gross Margin
Q2 gross margin reached 56%, up from 41% in Q1 and above the prior high of 50% in Q4 2025; year-to-date 2026 margin is 50%.
Strong Commercial Momentum and Access
More than 95 ATCs active (on track to reach ≥110 by year-end); commercial Amtagvi provided to >50 patients per month; >95% of patients live within 200 miles of a U.S. ATC and 80% within 100 miles.
Robust Clinical and Real-World Evidence
Published 5-year durability data and real-world response rates >50% in patients with ≤2 prior lines of therapy; estimated 10-year overall survival for responders ~46.7% from new survival analysis.
Pipeline Progress and Regulatory Milestones
LUN-202 enrollment nearly complete (non-squamous NSCLC) with intent to pursue supplemental BLA in 2027; SARATOGA (SAR-201/lifileucel) granted FDA Fast Track designation for undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Promising Early Signals in Additional Indications
END-201 (metastatic serous endometrial cancer) early data: 40% confirmed objective response rate and 100% disease control rate (first 5 evaluable patients); pilot lifileucel showed 50% ORR in first 6 evaluable sarcoma patients.
Manufacturing Scale and Operational Efficiency
First full quarter of exclusively in-house manufacturing with turnaround time of 31 days or less; ongoing cost optimization and AI deployment supporting future efficiencies.
Financial Position and Operational Discipline
Cash, cash equivalents, and short-term investments of ~$304M as of June 30, 2026, expected to fund operations into H2 2028; R&D expenses declined to ~$59M (down from $62M prior quarter) marking fourth consecutive quarter of R&D optimization; SG&A stable at ~$39M despite revenue growth.
DE:2LB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed